Tumor necrosis factor induced protein 3 gene polymorphism and the susceptibility to chronic primary immune thrombocytopenia in Egyptian children: a case-control study
Background Primary immune thrombocytopenia (PIT) is an acquired auto-immune disease characterized by decreased platelet count with increased bleeding tendency. The tumor necrosis factor associated induced protein-3 (TNFAIP3) codes for the ubiquitin-modifying enzyme that is indispensable for limiting...
Gespeichert in:
Veröffentlicht in: | Egyptian Journal of Medical Human Genetics 2021-02, Vol.22 (1), p.12-9, Article 12 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background
Primary immune thrombocytopenia (PIT) is an acquired auto-immune disease characterized by decreased platelet count with increased bleeding tendency. The tumor necrosis factor associated induced protein-3 (TNFAIP3) codes for the ubiquitin-modifying enzyme that is indispensable for limiting inflammation. TNFAIP3 single-nucleotide polymorphisms (SNP) has been implicated in the susceptibility to multiple auto-immune diseases. We aimed to study the distribution of TNFAIP3 (
rs5029939 C>G
) SNP and the possible association of the studied polymorphism with the susceptibility to chronic PIT and the response to treatment in a sample of the Egyptian pediatric chronic PIT patients. This is a case-control study performed on 40 chronic PIT patients and 50 age- and gender-matched healthy controls. DNA samples from both groups were tested for TNFAIP3 (
rs5029939 C
>
G
) SNP using polymerase chain reaction-restriction fragment length polymorphism assay.
Results
TNFAIP3 (
rs5029939 C
>
G
) genotype distribution showed no statistically significant difference between PIT cases and controls [CC 77.5% vs. 82.5%, and CG 22% vs. 18%, respectively; OR (95% CI), 1.323 (0.470–0.723);
p
, 0.596]. The minor allele frequency (MAF) of
rs5029939
-
G
was comparable between the 2 groups (0.11 vs. 0.09) [OR (95% CI), 1.282 (0.484–3.397);
p
, 0.617]. No statistically significant difference was observed between chronic PIT patients carrying the mutant heterozygous genotype (CG) achieving complete response and those with no response [OR (95% CI), 1.667 (0.165-16.810);
p
> 0.05]. The MAF of
rs5029939
-
G
was comparable between both groups [OR (95% CI), 1.571 (0.175–14.111);
p
> 0.05].
Conclusion
This study showed no liability of patients carrying TNFAIP3 (
rs5029939 C
>
G
) polymorphism to develop chronic course of the disease or to achieve complete response to treatment. TNFAIP3 (
rs5029939 C < G
) SNP plays no role in either susceptibility to chronic PIT in the studied sample of Egyptian pediatric population or their response to treatment. |
---|---|
ISSN: | 2090-2441 1110-8630 2090-2441 |
DOI: | 10.1186/s43042-020-00129-6 |